Unknown

Dataset Information

0

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.


ABSTRACT: AIM:Warfarin pharmacogenomic algorithms reduce dosing error, but perform poorly in non-European-Americans. Electronic health record (EHR) systems linked to biobanks may allow for pharmacogenomic analysis, but they have not yet been used for this purpose. PATIENTS & METHODS:We used BioVU, the Vanderbilt EHR-linked DNA repository, to identify European-Americans (n = 1022) and African-Americans (n = 145) on stable warfarin therapy and evaluated the effect of 15 pharmacogenetic variants on stable warfarin dose. RESULTS:Associations between variants in VKORC1, CYP2C9 and CYP4F2 with weekly dose were observed in European-Americans as well as additional variants in CYP2C9 and CALU in African-Americans. Compared with traditional 5 mg/day dosing, implementing the US FDA recommendations or the International Warfarin Pharmacogenomics Consortium (IWPC) algorithm reduced error in weekly dose in European-Americans (13.5-12.4 and 9.5 mg/week, respectively) but less so in African-Americans (15.2-15.0 and 13.8 mg/week, respectively). By further incorporating associated variants specific for European-Americans and African-Americans in an expanded algorithm, dose-prediction error reduced to 9.1 mg/week (95% CI: 8.4-9.6) in European-Americans and 12.4 mg/week (95% CI: 10.0-13.2) in African-Americans. The expanded algorithm explained 41 and 53% of dose variation in African-Americans and European-Americans, respectively, compared with 29 and 50%, respectively, for the IWPC algorithm. Implementing these predictions via dispensable pill regimens similarly reduced dosing error. CONCLUSION:These results validate EHR-linked DNA biorepositories as real-world resources for pharmacogenomic validation and discovery.

SUBMITTER: Ramirez AH 

PROVIDER: S-EPMC3361510 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Aim</h4>Warfarin pharmacogenomic algorithms reduce dosing error, but perform poorly in non-European-Americans. Electronic health record (EHR) systems linked to biobanks may allow for pharmacogenomic analysis, but they have not yet been used for this purpose.<h4>Patients & methods</h4>We used BioVU, the Vanderbilt EHR-linked DNA repository, to identify European-Americans (n = 1022) and African-Americans (n = 145) on stable warfarin therapy and evaluated the effect of 15 pharmacogenetic varian  ...[more]

Similar Datasets

| S-EPMC3621954 | biostudies-literature
| S-EPMC2586955 | biostudies-literature
| S-EPMC2756088 | biostudies-literature
| S-EPMC2757655 | biostudies-literature
| S-EPMC5619051 | biostudies-literature
2018-05-18 | GSE104131 | GEO
2017-08-04 | GSE102286 | GEO
2017-07-28 | GSE101929 | GEO
| S-EPMC8238796 | biostudies-literature
| S-EPMC4016191 | biostudies-literature